The next boom in Pharma market – BIOLOGICS & BIOSIMILARS Naresh Kumar KalagataMarch 31, 2016 Comments
Applications for compulsory license (CL) of patents in India: Sorafenib tosylate successful, Dasatinib rejected, Saxagliptin rejected. Naresh Kumar KalagataMarch 7, 2016 Comment
Are you infusing startup energy in your venture? Prashant BOctober 8, 2015pharma, startup, talent, formulations, CROComment